Twenty-five years with adjuvant chemotherapy for colon cancer – a continuous evolving concept

References

• Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer 1975;36:675–82.
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447–56.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.
   PubMed Web of Science ®Google Scholar
• Conference, National Institutes of Health. Adjuvant therapy for colon and rectal cancer. JAMA 1990;264:1444–50.
   PubMed Web of Science ®Google Scholar
• Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 2009;48:368–76.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005;44:904–12.
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Hafström LO, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282–308.
   PubMed Web of Science ®Google Scholar
• Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 2015;54:5–16.
   PubMed Web of Science ®Google Scholar
• Glimelius B. 50 years with Acta Oncologica. Acta Oncol 2013;52:1–2.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Johansen C, Muren LP, Nilbert M. Acta Oncologica and a new generation of scientists in oncology. Acta Oncol 2014;53:849–51.
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852–64.
   PubMed Web of Science ®Google Scholar
• MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457–60.
   PubMed Web of Science ®Google Scholar
• Wibe A, Carlsen E, Dahl O, Tveit KM, Wedon-Fekjaer H, Hestvik UE, et al. Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 2006;8:224–9.
   PubMed Web of Science ®Google Scholar
• Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedermark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93–6.
   PubMed Web of Science ®Google Scholar
• Hohenberger P, Du W, Post S. Extended resections for colorectal cancer – indications for supraradical lymphadenectomy. Colorectal Dis 2011;13(Suppl 7):74–7.
   PubMed Web of Science ®Google Scholar
• Sondenaa K, Quirke P, Hohenberger P, Sugihara K, Kobayashi H, Kessler H, et al. The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: Proceedings of a consensus conference. Int J Colorectal Dis 2014;29:419–28.
   PubMed Web of Science ®Google Scholar
• West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, et al. Understanding optimal colonic cancer surgery: Comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol 2012;30:1763–9.
   PubMed Web of Science ®Google Scholar
• Munkedal DLE, West NP, Iversen LH, Hagemann-Madsen R, Quirke P, Laurberg S. Implementation of complete mesocolic excision at a university hospital in Denmark: An audit of consecutive, prospectively collected colon cancer specimens. Eur J Surg Oncol 2014;40:1494–501.
   PubMed Web of Science ®Google Scholar
• Jullumstro E, Wibe A, Lydersen S, Edna TH. Colon cancer incidence, presentation, treatment and outcomes over 25 years. Colorectal Dis 2011;13:512–8.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, West NP, van Krieken JH, Quirke P. Pathology is a necessary and informative tool in oncology clinical trials. J Pathol 2014;232:185–9.
   PubMed Web of Science ®Google Scholar
• Jestin P, Påhlman L, Glimelius B, Gunnarson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination. Eur J Cancer 2005;41:2071–8.
   PubMed Web of Science ®Google Scholar
• Iachetta F, ReggianiBonetti L, Marcheselli L, Di Gregorio C, Crilli C, Messinese S, et al. Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study. Acta Oncol 2013; 52:1682–90.
   PubMed Web of Science ®Google Scholar
• Nedrebø BS, Søreide K, Nesbakken A, Eriksen MT, Søreide JA, Kørner H; Norwegian Colorectal Cancer Group. Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Dis 2013;15:e301–8.
   Google Scholar
• Soreide K, Nedrebø BS, Søreide JA, Sleva A, Kørner H. Lymph node harvest in colon cancer: Influence of microsatellite instability and proximal tumor location. World J Surg 2009;33:2695–703.
   PubMed Web of Science ®Google Scholar
• Huh JW, Kim YJ, Kim HR. Ratio of metastatic to resected lymph nodes as a prognostic factor in node-positive colorectal cancer. Ann Surg Oncol 2010;17:2640–6.
   PubMed Web of Science ®Google Scholar
• Stanisavljevic L, Søndenaa K, Storli KE, Leh S, Nesvik I, Gudlaugsson E, et al. The total number of lymph nodes in resected colon cancer specimens is affected by several factors but the lymph node ratio is independent of these. APMIS 2014;122:490–8.
   PubMed Web of Science ®Google Scholar
• Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: Evidence of stage migration from the ACCENT database. J Clin Oncol 2013;31:3656–63.
   PubMed Web of Science ®Google Scholar
• West NP, Sutton KM, Ingeholm P, Hagemann-Madsen R, Hohenberger W, Quirke P. Improving the quality of colon cancer surgery through a surgical education program. Dis Colon Rect 2010;53:1594–603.
   PubMed Web of Science ®Google Scholar
• van Gils CW, Koopman M, Mol L, Redekop WK, Ulyl-de Groot CA, Punt CJ. Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncol 2012;51:57–64.
   PubMed Web of Science ®Google Scholar
• van den Broek CB, Bastiaannet E, Dekker JW, Portielje JE, de Craen AJ, Elferink MA, et al. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008. Acta Oncol 2013;52:941–9.
   PubMed Web of Science ®Google Scholar
• Lin HH, Chang YY, Lin JK, Jiang JK, Lin CC, Lan YT, et al. The role of adjuvant chemotherapy in stage II colorectal cancer patients. Int J Colorectal Dis 2014;29:1237–43.
   PubMed Web of Science ®Google Scholar
• Berg M, Guriby M, Nordgård O, Nedrebø BS, Ahlquist TC, Smaaland R, et al. Influence of microsatellite instability, KRAS and BRAF mutations on lymph node harvest in stage I–III colon cancers. Mol Med 2013; (in press).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: Prospective evaluation of biomarkers for stages II and III colon cancer – a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153–62.
   PubMed Web of Science ®Google Scholar
• Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: Results from a large, consecutive Norwegian series. Ann Oncol 2013;24:1274–82.
   PubMed Web of Science ®Google Scholar
• Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevoll K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009;101:1282–9.
   PubMed Web of Science ®Google Scholar
• Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, et al. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer 2012;107:1684–91.
   PubMed Web of Science ®Google Scholar
• Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: The dawning of a new era. Oncologist 2014;19:568–73.
   PubMed Web of Science ®Google Scholar
• Sadanandam A, Wang X, de Sousa e Melo F, Gray JW, Vermeulen L, Hanahan D, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619–25.
   PubMed Web of Science ®Google Scholar
• Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, et al. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: Is Godot finally arriving? Clin Cancer Res 2013;19:6669–77.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hikish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16.
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768–74.
   PubMed Web of Science ®Google Scholar
• Church DN, Midgley R, Kerr D. Stage II colon cancer. Chin Clin Oncol 2013;2:16.
   PubMedGoogle Scholar
• Tournigand C, Andre T, Bonnetain F, Chibaudel B, Liedo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353–60.
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: Findings from the ACCENT database. J Clin Oncol 2013;31:2600–6.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007;25:3456–61.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117–25.
   PubMed Web of Science ®Google Scholar
• Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20:674–80.
   PubMed Web of Science ®Google Scholar
• Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial. Lancet Oncol 2014;15:862–73.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012;307:1383–93.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11–6.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225–33.
   PubMed Web of Science ®Google Scholar
• Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: Prospective combined analysis of phase III Trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status. Curr Colorectal Cancer Rep 2013;9:261–9.
   PubMedGoogle Scholar
• Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol 2008;19:400–2.
   PubMed Web of Science ®Google Scholar
• Dighe S, Swift I, Magill L, Handley K, Gray R, Quirke P, et al. Accuracy of radiological staging in identifying high- risk colon cancer patients suitable for neoadjuvant chemotherapy: A multicentre experience. Colorectal Dis 2011; 14:438–44.
   Web of Science ®Google Scholar
• Norgaard A, Dam C, Jakobsen A, Pløen J, Lindebjerg J, Rafaelsen SR. Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan. Scand J Gastroenterol 2014;49:202–8.
   PubMed Web of Science ®Google Scholar
• Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. Lancet Oncol 2012;13:1152–60.
   PubMed Web of Science ®Google Scholar
• Arredondo J, Gonzalez I, Baixauli J, Martinez P, Roderiguez J, Pastor C, et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol 2014;5:104–11.
   PubMedGoogle Scholar
• Arredondo J, Pastor C, Baixauli J, Rodriguez J, Gonzalez I, Vigil C, et al. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Dis 2013;15:552–7.
   PubMed Web of Science ®Google Scholar